Page 9 - Remunity Pump News Today

StockNews.com downgraded shares of United Therapeutics (NASDAQ:UTHR – Free Report) from a strong-buy rating to a buy rating in a report issued on Friday morning. Several other research firms also recently weighed in on UTHR. LADENBURG THALM/SH SH lowered their price objective on shares of United Therapeutics from $285.00 to $256.00 in a report on […]

Victory Capital Management Inc. increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 32.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,671 shares of the biotechnology company’s stock after acquiring an additional 7,046 shares during […]

The following discussion should be read in conjunction with our consolidated financial statements and related notes to our consolidated financial statements. All statements in this filing are made as of the date this Report is filed with the U.S. Securities and Exchange Commission. These statements, which are based on our beliefs and expectations about...

SAN FRANCISCO, Feb. 10, 2022 /PRNewswire/ -- The global pulmonary arterial hypertension market size is anticipated to reach USD 11.0 billion by 2030, according to a new report by Grand View

/PRNewswire/ -- The global pulmonary arterial hypertension market size is anticipated to reach USD 11.0 billion by 2030, according to a new report by Grand...

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the...

Message : Required fields SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 5, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2021. Total revenue in the first quarter of 2021 grew 6% year over year to $379.1 million, compared to $356.3 million in the first quarter of 2020. "2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of...

United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETON study of Tyvaso in idiopathic pulmonary fibrosis (IPF) expected to enroll its first patients in the second quarter of 2021 News provided by Share this article Share this article SILVER SPRING, Md. ...

MedCity News United Therapeutics notches another FDA approval for lung drug The FDA decision for Tyvaso as a treatment for pulmonary arterial hypertension in patients who have interstitial lung disease is the second approval for the United Therapeutics drug. The additional indication gives the company another way to grow revenue for the drug, which faces generic competition. Shares0   United Therapeutics has received FDA approval for its drug, treprostinil, as a treatment for high blood pres...

United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin® News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity ® Pump for Remodulin ® for patients with pulmonary arterial hypertension (PAH). "We are excited to bring to market the first subcutaneous pump...